Von Hippel Lindau (VHL) (C-term) Rabbit Polyclonal Antibody

CAT#: AP17826PU-N

Von Hippel Lindau (VHL) (C-term) rabbit polyclonal antibody

Product Images

Western blot analysis of VHL antibody (C-term) in HepG2 cell line lysates (35ug/lane). VHL (arrow) was detected using the purified Pab.

Specifications

Product Data

• Applications: WB
• Recommended Dilution: ELISA: 1/1,000.
  Western blotting: 1/50 - 1/100.
• Reactivities: Human
• Host: Rabbit
• Clonality: Polyclonal
• Immunogen: KLH conjugated synthetic peptide selected from the C-terminal region of human VHL
• Specificity: This antibody reacts to VHL.
• Formulation: PBS with 0.09% (W/V) sodium azide
  State: Liquid purified Ig
• Concentration: lot specific
• Purification: Saturated Ammonium Sulfate (SAS) precipitation
• Storage: Store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer.
  Avoid repeated freezing and thawing.
• Stability: Shelf life: one year from despatch.
• Gene Name: Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1
• Database Link:
  Entrez Gene 7428 Human
• Background: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of VHL gene is the basis of familial inheritance of VHL syndrome. The protein is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein.
• Synonyms: Von Hippel-Lindau disease tumor suppressor

Reference Data

• Protein Families: Druggable Genome, Transcription Factors
• Protein Pathways: Pathways in cancer, Renal cell carcinoma, Ubiquitin mediated proteolysis